Results 121 to 130 of about 43,858 (197)

GENERATIVE AI TOWARDS A COMPARATIVE ANALYSIS OF HOSPITALIZATION RATES AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH INFLIXIMAB, VEDOLIZUMAB, AND TOFACITINIB IN THE PUBLIC HEALTHCARE SYSTEM IN BRAZIL: A NATIONWIDE STUDY. [PDF]

Arq Gastroenterol
Valverde DA, Quaresma AB, Villamil MPG, Moraes TP, Kotze PG.   +4 more
europepmc   +1 more source

Exosome‐Mediated Delivery of PROTACs for Targeted Protein Degradation in Cancer, Neurodegenerative, Infectious, and Inflammatory Diseases

Journal of Cellular and Molecular Medicine, Volume 30, Issue 15, August 2026.
ABSTRACT Proteolysis‐targeting chimeras (PROTACs) are heterobifunctional molecules that hijack the ubiquitin‐proteasome system to drive catalytic, sub‐stoichiometric degradation of disease‐associated proteins, offering a mechanistic advantage over occupancy‐driven inhibitors and access to ‘undruggable’ targets.
Sruti Bagchi Ghosh, Rumpa Banerjee, Hailah M. Almohaimeed, Amany I. Almars, Tahani Ahmad ALMatrafi, Fayez M. Saleh, Zuhair M. Mohammedsaleh, Kranti Kiran Reddy Ealla, Ajoy Kumer, Bikram Dhara   +9 more
wiley   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1318-1331, August 2026.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

Efficacy and Safety Profile of Oral Tofacitinib in Non-Segmental Vitiligo. [PDF]

Indian J Dermatol
Jagadeesan S, Prasad N, Duraiswamy P, Panicker VV.   +3 more
europepmc   +1 more source

Five‐Year Outcomes and Disease Trajectories in Moderate‐to‐Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort

Journal of Gastroenterology and Hepatology, Volume 41, Issue 8, Page 2338-2348, August 2026.
ABSTRACT Background and Aim The incidence of ulcerative colitis (UC) has been increasing in Asia. Comprehensive data on the long‐term course of moderate‐to‐severe UC remain scarce. This study investigated the clinical outcomes and factors associated with a disabling disease course in Korean patients with moderate‐to‐severe UC.
Byong Duk Ye, Hyo Jong Kim, Dong Il Park, Young Sook Park, Kang‐Moon Lee, Jong Pil Im, Sung‐Ae Jung, Yoon Tae Jeen, Jae Myung Cha, Jae Hee Cheon, Sung Noh Hong, Youngdoe Kim, Jong Min Choi, YoungJa Lee, Chang Kyun Lee   +14 more
wiley   +1 more source

Real-World Effectiveness of Biologic and Targeted Synthetic Therapies in Rheumatoid Arthritis: a Multicenter Study from Rheumatoid Arthritis Saudi Database (RASD). [PDF]

Open Access Rheumatol
Almoallim HM, Bahlas SM, Bawazir Y, Hussein AH, Attia GM, Manasfi H, Bafadhl ZA, Asiri AM, Ali AR, Alomair MM, Alsharaif MM, Almalki HH, Siddiqui MI, Alhazmi AS, Attar SM.   +14 more
europepmc   +1 more source

Efficacy and safety of dual-targeted therapy with tofacitinib and TNF inhibitors in refractory spondyloarthritis: a case series from a tertiary care center. [PDF]

Ther Adv Musculoskelet Dis
Agrawal A, Yadav SS, Balakrishnan C.
europepmc   +1 more source

Real-World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi-Center Cohort Study. [PDF]

Clin Transl Sci
Jin Y, Cao J, Yang S, Liu Y, Tang R, Zeng Y, Huang C, Luo Y.   +7 more
europepmc   +1 more source

Extended High-Dose Tofacitinib Induction Improves Clinical Response in Ulcerative Colitis: A Multicenter Cohort Study. [PDF]

JGH Open
Gilmore R, Pham T, Fernandes RG, Lo S, Wright EK, Rosella O, De Cruz P, Andrew B, Vasudevan A, Gazelakis K, Moore GT, Thin L, Au K, Ghaly S, Chen C, Mohsen W, Goodwin T, Sparrow MP, Ward MG, Chew M, Garg M, Shelton E, Lawrance IC, Thorat A, da Fonseca Pereira C, Begun J, An YK.   +26 more
europepmc   +1 more source

Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study. [PDF]

Adv Ther
Tursi A, Pasta A, Elisei W, Barberio B, Mocci G, Savarino EV, de Barba C, Maconi G, Cataletti G, Scaldaferri F, Napolitano D, Costa F, Ceccarelli L, Marzo M, Monterubbianesi R, di Fonzo M, Lombardi G, Patturelli M, Ribaldone DG, Bertani L, Rodino' S, Sebkova L, Bodini G, Pranzo G, Serio M, Scarcelli A, Luppino I, Ferronato A, Spagnuolo R, Luzza F, Morano D, Gravina AG, Pellegrino R, Vespere G, Sedda S, Allegretta L, Fanigliulo L, Grossi L, Cortellini F, Forti G, Neve V, Piergallini S, Scarozza P, Bevevino G, Iacopini F, Capone P, Gaiani F, Kayali S, Mucherino C, D'antonio E, D'ascoli B, Colucci R, Bachetti F, Giorgetti GM, Clemente V, Pagnini C, Cuomo A, Donnarumma L, Onidi FM, Satta PU, Picchio M, Papa A, Italian Network for Inflammatory Bowel Diseases (IN-IBD).   +62 more
europepmc   +1 more source